Pfizer Inc. (PFE) to Issue Quarterly Dividend of $0.43 on December 7th

Pfizer Inc. (NYSE:PFE) declared a quarterly dividend on Tuesday, October 6th. Stockholders of record on Friday, November 6th will be paid a dividend of $0.43 per share by the biopharmaceutical company on Monday, December 7th. This represents a $1.72 annualized dividend and a dividend yield of 5.7%. The ex-dividend date is Friday, November 6th.

Pfizer has decreased its dividend payment by an average of 0.1% annually over the last three years and has increased its dividend every year for the last 16 years. Pfizer has a payout ratio of 55.8% indicating that its dividend is sufficiently covered by earnings. Analysts expect Pfizer to earn $2.95 per share next year, which means the company should continue to be able to cover its $1.72 annual dividend with an expected future payout ratio of 58.3%.

Pfizer Stock Down 2.3%

PFE stock opened at $29.98 on Wednesday. The firm has a market cap of $170.85 billion, a PE ratio of 39.44, a P/E/G ratio of 2.08 and a beta of 0.31. Pfizer has a 12 month low of $23.62 and a 12 month high of $31.06. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.27 and a quick ratio of 0.96. The firm has a 50 day simple moving average of $28.64 and a 200 day simple moving average of $26.84.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, November 3rd. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.74 by $0.13. The firm had revenue of $16.58 billion for the quarter, compared to analyst estimates of $15.85 billion. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The firm’s quarterly revenue was down .4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.87 earnings per share. Equities research analysts forecast that Pfizer will post 2.94 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. Pictet Asset Management Holding SA boosted its position in shares of Pfizer by 62.8% during the 3rd quarter. Pictet Asset Management Holding SA now owns 4,721,719 shares of the biopharmaceutical company’s stock worth $134,667,000 after acquiring an additional 1,820,944 shares in the last quarter. Leelyn Smith LLC increased its stake in Pfizer by 3.9% in the third quarter. Leelyn Smith LLC now owns 128,235 shares of the biopharmaceutical company’s stock valued at $3,657,000 after acquiring an additional 4,851 shares during the last quarter. Verus Capital Partners LLC increased its stake in Pfizer by 5.1% in the third quarter. Verus Capital Partners LLC now owns 16,716 shares of the biopharmaceutical company’s stock valued at $477,000 after acquiring an additional 805 shares during the last quarter. W.G. Shaheen & Associates DBA Whitney & Co acquired a new position in Pfizer during the third quarter valued at approximately $221,000. Finally, Pathway Financial Advisers LLC raised its position in Pfizer by 17.3% during the third quarter. Pathway Financial Advisers LLC now owns 67,908 shares of the biopharmaceutical company’s stock valued at $1,937,000 after purchasing an additional 10,005 shares in the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

About Pfizer

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.

The company’s portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.

Founded in Brooklyn, New York, in 1849 by Charles Pfizer and Charles Erhart, Pfizer has grown into an international healthcare company serving patients and healthcare providers in markets around the world.